Mon premier blog

Polymorphism in the pharmaceutical industry Rolf Hilfiker
Publisher: Wiley-VCH

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more. This training is being organized jointly by Shanghai Institute of Pharmaceutical Industry (SIPI), Shanghai Eterpharm Inc., and METTLER TOLEDO. Edited by one of the leading experts in the field, this handbook emphasizes why solid-state issues are important, which approaches should be taken to avoid. Even in the US, generic companies successfully launched generic products having different polymorphic forms from the drug substances in the respective RLD (e.g., ranitidine, cefadroxil, terazosin etc.). This text introduces the basic concepts and discusses their wider implication for pharmaceutical development, with reference to many case examples of current drugs and drug products. This is all to do with a phenomenon known as polymorphism, which is the ability for a solid to exist in more than one crystal structure. Each crystal structure is called a polymorph, and each polymorph has its own set of distinct only have implications on your chocolate, but on almost anything that can crystallise. There are many patent issues with regards to the different polymorphs of drug molecules in the pharmaceutical industry, and a range of other industries. Of Health and published in Gut. To follow text highlighted with relevant pharmaceutical examples; Self-assessment assignments in a variety of formats; Written by authors with both academic and industrial experience; Companion website with further information to maximise learning 7.4.1 Thermodynamics of polymorphism 133. Integrated Process Research and Development by Solvias: Basis of an Efficient and Successful Drug Substance Development in the Pharma Industry. Pharmaceuticals companies are constantly battling the problem of polymorphism in which an active drug can actually exist in more than one form or crystal structure which can cause the drug to act in very different ways. The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Pharma-IQ.com serves the pharma and biotech community with complimentary access to an exclusive library of keeping them up-to-date with industry trends, technological developments and the regulatory landscape. Comprehensive reference for researchers in the field of cancer pharmacogenomics and clinicians, from both academia and industry; Provides a collection of multi-disciplinary topics; Covers the most important aspects of pharmacogenomics applied to cancer patients. A letter on understanding triphasic HCV decline during treatment in the era of IL28B polymorphisms and direct acting antiviral agents via mathematical modeling, published in the Journal of Hepatology. Pharma IQ Events include: Cool Chain, Compound Management, Polymorphism & Crystallisation and Lean Six Sigma for Pharma. Category: Drug Solid state investigations including salt selection, polymorphism screening, and crystallization optimization programs enable customers to prepare the optimal solid form of a drug substance with well-defined properties for manufacture of the corresponding drug product. Pharma-IQ.com is a new online network and content resource designed exclusively for the pharmaceutical industry. Screening for polymorphs is crucial for drug research and development, since the crystal form of the active pharmaceutical ingredient (API) directly correlates with its pharmacokinetic properties.